Floatz logo

Satraplatin

Disease Of Genetic Or Genomic Mechanism

Explore 13 assets in Disease Of Genetic Or Genomic Mechanism →
Floatz Rating
CCC50/100
Confidence
Indicative
v0.2
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
35Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT00634647CT.gov
Satraplatin and Prednisone to Treat Prostate Cancer
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Disease Of Genetic Or Genomic Mechanism

AssetSponsorPhaseRating
Satraplatin (this asset)National Cancer Institute (NCI)P2CCC · 50
GuanfacineMaimonides Medical CenterP4BB
Autologous Cd34+ Cells Isolated From Mobilised Peripheral Blood By Positive Selection, Modified By Crispr/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/Crispr-Associated Protein 9) Mediated Gene Editing Consisting Of A Guide Rna (Grna) Introduced Transiently As Ribonucleoprotein (Rnp) Complex, Targeting The Erythroid Lineage-Specific Enhancer Region Of Bcl11A (B-Cell Lymphoma/Leukemia 11A). The Site-Specific Cleavage By Cas9 Forms A Double Strand Break (Dsb), Which Is Subsequently Repaired By Nonhomologous End-Joining (Nhej), Leading To The Transcriptional Repression Of Bcl11A, A Repressor Of ?-Globin Gene TranscriptionVertex Pharmaceuticals IncorporatedP3BB
AtalurenPTC TherapeuticsP3B
DeramiocelCapricor Inc.P3B
Human Allogeneic Cardiosphere-Derived CellsCapricor Inc.P2B
PrednisoneInstituto do Cancer do Estado de São PauloP2B
IvonescimabMassachusetts General HospitalP2CCC
CarboplatinMassachusetts General HospitalP2CCC

+13 more in the Disease Of Genetic Or Genomic Mechanism cohort

Other indications for Satraplatin

IndicationSponsorPhaseRating
Non-Small Cell Lung Carcinoma—P2CCC · 55
Prostate Cancer—P3CCC · 54
Lung Cancer—P2CCC · 49

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Satraplatin in Disease Of Genetic Or Genomic Mechanism. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/satraplatin-disease-of-genetic-or-genomic-mechanism

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →